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Abstract
Dogs with naturally occurring cancer represent an important large animal model for drug development and testing novel
immunotherapies. However, poorly defined immunophenotypes of canine leukocytes have limited the study of tumor
immunology in dogs. The accumulation of myeloid derived suppressor cells (MDSCs) is known to be a key mechanism of
immune suppression in tumor-bearing mice and in human patients. We sought to identify MDSCs in the blood of dogs with
cancer. Peripheral blood mononuclear cells (PBMCs) from dogs with advanced or early stage cancer and from age-matched
healthy controls were analyzed by flow cytometry and microscopy. Suppressive function was tested in T cell proliferation
and cytokine elaboration assays. Semi-quantitative RT-PCR was used to identify potential mechanisms responsible for
immunosuppression. PBMCs from dogs with advanced or metastatic cancer exhibited a significantly higher percentage of
CD11b
+CD14
2MHCII
2 cells compared to dogs diagnosed with early stage non-metastatic tumors and healthy dogs. These
CD11b
+ CD14
2MHCII
2 cells constitute a subpopulation of activated granulocytes that co-purify with PBMCs, display
polymorphonuclear granulocyte morphology, and demonstrate a potent ability to suppress proliferation and IFN-c
production in T cells from normal and tumor-bearing donors. Furthermore, these cells expressed hallmark suppressive
factors of human MDSC including ARG1, iNOS2, TGF-b and IL-10. In summary our data demonstrate that MDSCs accumulate
in the blood of dogs with advanced cancer and can be measured using this three-marker immunophenotype, thereby
enabling prospective studies that can monitor MDSC burden.
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Introduction
Cancer is the leading cause of death in adult dogs in the United
States, Australia, Japan and Europe and is considered the major
health care concern of pet owners. Approximately four million
dogs are diagnosed with cancer each year in the United States [1].
Naturally occurring malignances in dogs share many features with
human cancers including similar tumor biology, genetics,
incidence rates, histological appearance, and response to conven-
tional treatments (reviewed in [2]). Tumors in dogs progress
relatively faster than the same disease in humans, allowing
questions related to treatment efficacy (progression and survival)
to be addressed more rapidly in dogs. An important advantage of
the dog model is the ability to test experimental therapeutics at
human scale doses in the setting of minimal residual disease, which
is difficult to do in a meaningful way in small rodents that have
relatively rapid tumor growth kinetics. In addition, because the
standard of care for most canine tumors is poorly established, there
is much more flexibility in study design compared to human
clinical trials. Collectively these features make the dog an
outstanding platform for translational medicine.
Pet dogs with cancer are rapidly becoming an important tool
used in drug development. One of the best examples of this is the
recent parallel development of SU11654, a multi-targeted tyrosine
kinase inhibitor, and sunitinib malate (SU11248). Both drugs are
potent inhibitors of PDGFR, VEGFR, KIT, and FLT3. Studies in
dogs with various solid tumors revealed that plasma concentration
of SU11654, the mutational status of KIT, and the inhibition of
KIT phosphorylation were strongly predictive of clinical efficacy.
Optimal dosing parameters and toxicity were established in dogs
as well. These pioneering studies greatly facilitated the further
development of this entire class of drugs, most notably the
approval of sunitinib malate by the U.S. Food and Drug
Administration for the treatment of renal cell carcinoma (RCC)
and gastrointestinal stromal cell tumors, which often contain
similar KIT mutations [3]. It was later recognized that sunitinib
markedly depletes MDSCs and restores T cell function in human
RCC patients [4], an observation that could not have been made
in dogs at the time because of limited canine reagents and poorly
defined markers for canine leukocytes. We, and others, are testing
novel immune-based therapies in dogs with various malignancies,
but immune monitoring in these studies has been confounded by
the same problem. To put the field in perspective, a surface
immunophenotype for canine natural killer cells has not been
defined, the MHC alleles are poorly understood, and many of the
markers used rely on cross-reactive antibodies whereby specificity
must be tested empirically. It is crucial that new reagents are
developed and that the immunophenotypes of all major canine
leukocytes subsets are determined. Laying this basic foundation
will allow unique insights to be made as new small molecule drugs
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trials.
The accumulation of MDSCs in tumor-bearing mice and
humans with cancer is known to be a key mechanism of tumor
escape from immune surveillance [5,6,7]. MDSCs comprise a
phenotypically heterogeneous population of myeloid cells in early
stages of differentiation that expand in cancer and many other
pathological conditions, and have a potent ability to suppress T
cell function, especially T cell proliferation and effector cytokine
production [6,8]. MDSCs may be divided into monocytic and
granulocytic subtypes. One source of controversy in this field is
that MDSC heterogeneity has made comparisons between cancer
patients and murine tumor models challenging (see reference [9]
for excellent perspective). The molecular mechanisms by which
MDSCs inhibit T cell function are under investigation. Studies
have implicated up-regulation of arginase 1 (ARG1), inducible
nitric oxide synthase (iNOS2) and reactive oxygen species (ROS)
as important factors for MDSC-mediated immune suppression
[8,10,11]. ARG1 can profoundly impair T cell function at the
tumor site by L-arginine depletion, triggering the amino acid
starvation response and apoptosis in lymphocytes [7]. Another
mechanism of immune suppression is chemokine nitration, which
blunts effector T cell infiltration into the tumor site [12].
Furthermore, MDSC expansion is associated with downregulation
of L-Selectin on CD4
+ and CD8
+ T cells [13]. This reduces T cell
trafficking to secondary lymphoid organs where tumor-reactive T
cells can be primed [13]. Due to the ability of MDSCs to
downregulate the immune response against tumors in mice and in
humans, we hypothesized that these cells would also play an
important role in tumor-induced immune suppression in dogs with
cancer. Hence, the objective of this study was to identify surface
markers that characterize the existence of MDSCs in dogs.
Materials and Methods
Study Population and sample collection
The description of all dogs in this study is summarized in
Tables 1 and 2, with further detail provided in Tables S1 and
S2.
Table S3 is a summary of samples assayed in each figure.
Clinical data were obtained from medical records. Control dogs
were determined to be healthy based on physical examination,
owner observations and complete blood count exams. For dogs
with cancer, the diagnosis and tumor staging were based on
complete physical examinations, histopathology of tumor biopsy
specimens, blood work and specialized imaging tests, such as CT
scans, ultrasound or radiographs, to assess tumor location and size,
as well as the presence of metastatic disease. Dogs with large,
necrotic or multiple masses, lytic or severe bone destruction (with
osteosarcoma) or presence of metastasis, were placed into the
advanced stage/metastatic group. Animals presenting with small
masses or no metastatic nodules were placed into the early stage
non-metastatic group. Tables S1 and S2 also list specifics about
any treatment that dogs with cancer had received prior to or at the
time of blood collection for this study.
Blood samples from both cancer and healthy control dogs were
obtained specifically for this study. Samples were collected in
heparinized tubes by the Oncology and Community Practice
Services of the Veterinary Medical Center at the University of
Minnesota according to Institutional Animal Care and Use
Committee guidelines. The samples were drawn after the owners
signed the client consent form. The Institutional Animal Care and
Use Committee (IACUC) reviewed and approved the study
entitled as ‘‘Flow Cytometric Immunophenotyping of Peripheral
Blood Cells in Dogs’’ via designated member review under the
code number 0912A75493. Unless explicitly stated otherwise, the
cells being analyzed for this manuscript co-purified with peripheral
blood mononuclear cells (PBMCs) of dogs with cancer or age-
matched healthy controls that were isolated using Ficoll (Sigma)
gradient centrifugation as follows. Heparinized peripheral blood
was diluted 1:3 with sterile PBS (Invitrogen) and layered over
Ficoll-Histopaque (Sigma). Samples were centrifuged at 400-6 g
for 30 min. The PBMCs collected at the interface were transferred
to a fresh tube, washed twice with PBS, and resuspended with
freezing solution consisting of 90% fetal bovine serum (Invitrogen)
10% Dimethyl sulfoxide (DMSO) (Sigma) and then frozen at
280uC. Lastly, PBMCs were thawed for 2 minutes in a 37uC
water bath before staining and analysis. For analysis of fresh
samples, PBMCs were isolated as above, resuspended in FACS
buffer, stained with antibodies and immediately analyzed by flow
cytometry or FACS as indicated.
Table 1. Characteristics of dogs with cancer in the study.
Age (yrs) - Mean (Range) 9 (2–14)
Gender
Male/Neutered 22
Male/Intact 2
Female/Spayed 21
Processed Samples
Fresh 21
Frozen 24
Breed
Labrador Retriever 12
Mixed Breed 5
Golden Retriever 3
Greyhound 2
Boxer 2
Border Collie 2
Beagle 2
Scottish Terrier 1
Bull Mastiff 1
Rottweiler 1
Dalmatian 1
Great Dane 1
Bernese Mountain Dog 1
German Wirehaired Pointer 1
German Shepherd Dog 1
West Highland White Terrier 1
Gordon Setter 1
Weimaraner 1
Rhodesian Ridgeback 1
Rat Terrier 1
Newfoundland 1
Miniature Poodle 1
Chow Chow 1
English Springer Spaniel 1
Total 45
doi:10.1371/journal.pone.0033274.t001
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PBMC samples were isolated from fresh blood or thawed and
resuspended in FACS buffer. Nonspecific antibody binding was
blocked by pretreatment of cells with 10 mg/mL canine gamma-
globulin (Jackson Immunoresearch) for 20 min at room temper-
ature. Cells were first labeled using indirect staining with 0.1 mgo f
unconjugated mouse anti-dog CD11b antibody (clone
CA16.3E10, AbD Serotec) or IgG1 isotype control (AbD Serotec)
and 0.5 mg of PE-conjugated goat F(ab9)2 anti-mouse IgG (Abcam)
secondary antibody at 4uC for 30 min in a dark room. Following
indirect staining, cells were washed twice and stained with 0.3 mg
of FITC-conjugated rat anti-dog MHCII (clone YKIX334.2, AbD
Serotec) and 0.15 mg of the cross-reactive, Alexa fluor 647-
conjugated mouse anti-human CD14 antibody (clone TU ¨K4,
AbD Serotec) or isotypes controls at 4uC for 30 min in a dark
room according to manufacturer’s protocol. Antibody-labeled cells
were washed twice and re-suspended in FACS buffer. Cells were
incubated for 10 minutes at room temperature in the dark with 7-
amino-actinomycin D (7AAD, final concentration of 1 mg/mL;
Calbiochem) and then analyzed on a Becton Dickinson Canto
three-laser flow cytometer. Data were further analyzed with
FlowJo software (Tree Star). Analysis gates were set based on the
7AAD negative population. The percentage of MDSCs was
calculated based on the percentage of CD11b
+CD14
2MHCII
2
cells within the overall live PBMC population. In one experiment
(Figure S1), anti-mouse PE-conjugated CD11b (clone M1/70
eBioscience) and anti-mouse APC-conjugated Gr-1 (clone RB6-
8C5 eBioscience) antibodies were also used to verify cross-
reactivity with dog cells.
Isolation of MDSCs, PMNs and T cells
For functional assays, RT-PCR and cell morphology analysis,
fresh blood samples from a tumor-bearing dog were used for
isolation of CD11b
+CD14
2MHCII
2 or CD11b
+CD14
+MHCII
2
cells, as indicated, using a BD FACSAria cell sorter. For T cell
isolation, PBMCs were isolated as previously described from
fresh blood samples of healthy dogs and stained with 0.3 mgo f
FITC-conjugated mouse anti-dog CD3 (clone CA17.2A12, AbD
Serotec), 0.15 mg of Pacific blue-conjugated mouse anti-dog
CD4 (clone YKIX302.9, AbD Serotec) and 0.15 mgo f
Alexa700-conjugated mouse anti-dog CD8 (clone YCATE55.9,
AbD Serotec) antibodies. Polymorphonuclear leukocytes (PMN)
were purified from the cell pellet of a Ficoll gradient from
healthy dog blood samples, after removal of the PBMCs (at the
top of gradient) and erythrocytes by RBC lysis buffer
(eBioscience).
Ex Vivo Proliferation
Analysis of MDSC inhibitory activity on T cell proliferation
was measured by
3H-thymidine incorporation into DNA. Briefly,
PBMCs from the indicated dogs were seeded into U-bottom 96-
well plates (5610
4cells/well) in medium consisting of RPMI
1640 containing L-arginine (150 mM) (Invitrogen) supplemented
with penicillin/streptomycin (Invitrogen) and 10% heat-inacti-
vated fetal bovine serum (Invitrogen) at 37uC, in a 5% CO2
incubator. CD11b
+CD14
2MHCII
2 or CD11b
+ CD14
+
MHCII
2 cells from a dog with cancer were sorted and added
to cancer (autologous) or healthy responder PBMCs as indicated.
Concanavalin A (5 mg/ml) (Sigma) and recombinant human IL-
2 (10 IU/ml) (R&D systems) were used to stimulate T cell
proliferation. Non-stimulated PBMCs were used as negative
control. PBMCs or PMNs were co-cultured with healthy PBMCs
to control for the effect of simply adding additional cells to the
suppression assay as indicated. Plates were cultured for 72 h,
then pulsed with 1 mCi of
3H-thymidine (Amersham Pharmacia
Biotech) for 18 hrs at 37uC. Cells were harvested onto glass fiber
filters (Perkin Elmer), washed, dried, and counted. Proliferative
responses were measured by
3H-thymidine incorporation into
the DNA using a Matrix 96 Direct Beta Counter (Packard). All
experiments were performed in triplicate.
IFN-c Analyses
FACS-isolated CD11b
+CD14
2MHCII
2 cells from a cancer
dog were co-cultured with PBMCs isolated from a healthy dog
using the same method as the proliferation assay. After 72 hrs of
incubation the cell culture supernatants were collected and
measured using a Quantikine canine IFN-c ELISA kit according
to the manufacture’s instructions (R&D systems). Samples were
assayed colorimetrically, in triplicate, using a Microplate Reader
Synergy2 (Biotek) and analyzed with Microplate Data Collection
and Analysis Software Gen5 (Biotek).
Cytospin
FACS-isolated CD11b
+CD14
2MHCII
2 cells were stained
using a modified Giemsa stain (Diff-quick, Astral Diagnostics
Inc) for cell morphology evaluation and observed using a DME
microscope (Leica) at 636 power magnification. Pictures were
acquired with an EC3 camera (Leica).
RNA extraction and RT-PCR
RNA was extracted from FACS-isolated CD11b
+CD14
2
MHCII
2 cells or healthy dog PMNs, using an RNAeasy plus
Mini kit (QIAGEN) according to the manufacturer’s protocol.
Table 2. Characteristics of healthy dogs in the study.
Age (yrs) - Mean (Range) 8 (2–13)
Gender
Male/Neutered 7
Male/Intact 1
Female/Intact 2
Female/Spayed 8
Processed Samples
Fresh 6
Frozen 12
Breed
Labrador Retriever 4
Golden Retriever 2
English Setter 1
Shih Tzu 2
Mixed Breed 2
German Shepherd dog 1
German Wirehaired Pointer 1
Red Tick Hound 1
Poodle 1
Cocker Spaniel 1
Catahoula Hound mix 1
Greyhound 1
Total 18
doi:10.1371/journal.pone.0033274.t002
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spectrophotometer (Nanodrop). To detect expression of ARG1
and iNOS2 enzymes, gene-specific primers were designed based
on the canine ARG1 and iNOS2 sequence; primer sequences
for housekeeping gene were designed from canine b-actin gene
using Primer3Plus (http://www.bioinformatics.nl/cgi-bin/pri-
mer3plus/primer3plus.cgi). For detection of cytokines IL-10
and TGF-b, primer sequences of IL-10 and TGF-b were
obtained from published sources [14]. The BLAST algorithm
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to ensure
primer specificity to the target gene. First strand cDNA
synthesis was done using a QuantiTect Reverse Transcription
kit (QIAGEN). The two-step PCR reaction was carried out in a
12.5-ml volume containing 26SYBR green master mix (Quanta
Biosciences), 0.675U GoTaq Polymerase, 2 nM MgCl2 (Pro-
mega), 0.2 mM dNTPs (Stratagene), 0.2 mMo fe a c hp r i m e rp a i r
and 50 ng of cDNA template. Reaction conditions consisted of
initial denaturation at 94uCf o r2 m i n ,t h e nc y c l e so f
denaturation at 94uC for 30 s, annealing at 60uC for 45 s,
elongation at 72uC for 45 s and final elongation at 72uCf o r
5 min in a DNA Engine Thermal Cycler (Bio-rad). The
optimum annealing temperature for each primer pair was
established prior to the study (see primer sequences in Table
S4). PCR products were run on 2% agarose gels containing
0.5 ml/ml ethidium bromide and imaged under 590 nm ultra-
violet light on a Eagle Eye II image station (Stratagene).
Negative control reactions were performed using RNA that was
not subjected to reverse transcription PCR.
Statistical Analysis
The differences between two groups were analyzed using
unpaired, two-tailed Student’s t test. All tests were performed with
Prism 4 software (Graph Pad Software, Inc). P values ,0.05 were
considered to be statistically significant.
Figure 1. Immunophenotyping gating strategy and morphological analysis for MDSC identification in peripheral blood of dogs.
PBMCs from healthy dogs and dogs with cancer were stained for the myeloid marker CD11b, monocytic marker CD14 and MHC II. (A) Representative
flow cytometric analysis of forward and side scatter and gated CD11b
+CD14
2MHCII
2 cells from dogs with advanced or metastatic tumors compared
to dogs with early stage non-metastatic tumors and healthy control dogs. Plots are representative of dog with advanced metastatic
hemangiosarcoma (top), early stage bladder transitional cell carcinoma (middle) and a healthy dog. (B) FACS sorted CD11b
+CD14
2MHCII
2 cells were
stained with diff-quick for cell morphology evaluation. A representative example of polymorphonuclear granulocyte morphology of
CD11b
+CD14
2MHCII
2 cells is shown at 636magnification.
doi:10.1371/journal.pone.0033274.g001
MDSCs in Dogs with Spontaneous Cancer
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33274Results
Dogs with advanced cancer have elevated levels of
granulocytic CD11b
+CD14
2MHCII
2 cells that co-purify
with PBMCs
Peripheral blood samples from 45 dogs diagnosed with cancer
and 18 healthy control dogs were collected (Tables 1 and 2). All
dogs with cancer underwent clinical staging of their disease by
performing complete physical examinations, blood work, imag-
ing to assess tumor location and size and metastases, and
histopathological diagnosis made from diagnostic aspirate or
biopsy of the tumor. Among the 45 dogs diagnosed with cancer,
30 dogs were classified as having advanced or metastatic disease
and 15 dogs were classified as early stage/non-metastatic or low
grade disease based on clinical staging. Each group was further
subdivided according to histological diagnosis into sarcomas,
carcinomas or mast cell tumors (detailed in Tables S1 and S2).
The percentages of putative MDSCs in dogs with cancer and
healthy dogs were evaluated by flow cytometry. PBMCs from
dogs with advanced or metastatic cancer showed a marked
increase in the CD11b
+CD14
2MHCII
2 fraction of cells, which
accounted for the majority of the cells in the live cell gate,
compared to dogs diagnosed with early stage non-metastatic
tumors or healthy dog controls (Fig. 1A). This subset of cells
exhibited a polymorphonuclear granulocytic morphology at
heterogeneous stages of development (Fig. 1B), which resembles
a granulocytic subset of MDSCs identified in mice [15] and
humans [16].
Dogs with advanced or metastatic cancer had a significantly
greater fraction of putative MDSCs (36.0462.542, mean 6 SEM)
compared to dogs with early stage non metastatic tumors
(9.4060.953, mean 6 SEM) and healthy control dogs
(10.2461.412, mean 6 SEM) (Fig. 2A). Moreover, this elevation
in the CD11b
+CD14
2MHCII
2 fraction did not appear to be
restricted to a specific tumor type. The differences were statistically
significant in dogs with sarcomas, carcinomas, and mast cell
tumors compared with healthy controls (Fig. 2B). Conversely, the
percentage of CD11b
+MHCII
2 cells that did express CD14 was
not significantly different among any group. Therefore, the
frequency of CD11b
+CD14
2MHCII
2 cells that co-purify PBMCs
correlates with tumor burden. This finding is in agreement with
previously published data regarding MDSC levels and tumor
burden in mice and humans [17,18].
CD11b
+CD14
2MHCII
2 cells are functionally defined as
MDSCs
To test whether the CD11b
+CD14
2MHCII
2 subset was able to
inhibit T cell function, we conducted a series of co-culture
experiments. Purified CD11b
+CD14
2MHCII
2 cells from three
different subtypes of cancer were co-cultured with autologous or
healthy responder PBMCs. In all cases, CD11b
+CD14
2MHCII
2
cells exhibited a potent ability to suppress proliferative responses in
a dose-dependent manner. Representative examples of prolifera-
tive suppression are shown using samples from a dog with tonsillar
squamous cell carcinoma (Fig. 3A) and prostatic adenocarcinoma
(Fig. 3B). In order to determine if suppression was an artifact of
using responders from tumor-bearing dogs, we assayed for
proliferative suppression using normal responders. The addition
of CD11b
+CD14
2MHCII
2 cells, but not normal PMNs, impaired
the proliferation of PBMCs from healthy dogs (Fig. 3C).
Moreover, the amount of IFN-c secretion was assessed in the
conditioned medium from these co-cultures, revealing that
CD11b
+CD14
2MHCII
2 cells, but not normal PMNs, suppressed
the secretion of IFN-c (Fig. 3D).
Figure 2. Percentages of circulating CD11b
+CD14
2MHCII
2 cells in dogs with correlates with clinical tumor stage. (A) Analysis of
average CD11
+CD14
2MHCII
2 population frequency in dogs with advanced stage or metastatic tumors (n=30) compared with early stage non-
metastatic tumors (n=15) and control dogs (n=18). There was a significantly higher percentage of CD11b
+CD14
2MHCII
2 cells in dogs with
advanced cancer versus early stage non-metastatic tumors and healthy dogs (36.04% vs. 9.40% and10.24%, respectively. B) Average
CD11b
+CD14
2MHCII
2 population frequency in the major cancer subtypes: advanced stage or metastatic sarcomas (n=18), early stage non-
metastatic sarcomas (n=6), advanced stage or metastatic carcinomas (n=7) early stage non-metastatic carcinomas (n=7), advanced stage or
metastatic mast cell tumors (n=5) and early stage non-metastatic mast cell tumors (n=2) compared with control dogs (n=18). Significantly elevated
percentages were detected in all advanced tumors subtypes relative to early stage tumors and healthy dogs. Percentages of CD11b
+CD14
+MHCII
2
cells were not significant between groups (* indicates P,0.001). Mean 6 SEM are shown.
doi:10.1371/journal.pone.0033274.g002
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+ and CD8
+ T cells
To further interrogate the direct effect on T lymphocytes,
purified CD11b
+CD14
2MHCII
2 cells from a dog with osteosar-
coma were co-cultured with purified CD4
+ and CD8
+ T cells from
a healthy dog for 72 h. Non-stimulated cells and CD4
+ and CD8
+
cells co-incubated with healthy PBMCs were used as controls. As
expected, CD11b
+CD14
2MHCII
2 cells inhibited the prolifera-
tion of CD8
+ (Fig. 4A) and CD4
+ T cells (Fig. 4B) while PBMCs
from a normal dog did not. Taken together, these data
demonstrate that CD11b
+CD14
2MHCII
2 cells are indeed
functionally defined as canine MDSCs.
CD11b
+CD14
2MHCII
2 cells express hallmark MDSC-
derived immunosuppressive factors
It has been shown that MDSCs can inhibit T cell function by
the production of soluble factors such as arginase-1, reactive
oxygen species, nitric oxide and TGF-b (8–10). In order to assess
whether CD11b
+CD14
2MHCII
2 cells from dogs with cancer
could possibly utilize these mechanisms to mediate T cell
suppression, we evaluated the expression of ARG1 and iNOS2,
as well as the immunosuppressive cytokines TGF-b and IL-10,
within this cell population and from PMNs isolated from
peripheral blood of healthy dogs. PCR analysis of RNA extracted
from FACS isolated CD11b
+CD14
2MHCII
2cells confirmed the
expression of ARG-1, iNOS2 enzymes and immunosuppressive
cytokines TGF-b and IL-10 mRNA (Fig. 5A). In contrast, normal
dog PMNs did not express ARG1, although iNOS, TGF-b and
IL-10 mRNA were detectable (Fig. 5B). Because mRNA for
ARG-1, iNOS2, TGF- b and IL-10 were all found, we conclude
that these factors could play a role in the inhibition of T cell
proliferation and effector function. However, since PMNs isolated
from healthy dogs did not express detectable ARG-1 mRNA or
impair T cell function, suggesting that ARG-1 may be a tumor-
Figure 3. CD11b
+CD14
2MHCII
2 cells suppress T cell proliferation and cytokine elaboration. CD11b
+CD14
2MHCII
2 cells were sorted from
peripheral blood sample of dogs with cancer and then co-cultured with autologous PBMCs (A, B) or healthy dog PBMCs (C) in the presence of
mitogen for 72 hs. Representative examples from a total of eight dogs are shown. The graphs represent proliferative responses after addition of
CD11b
+CD14
2MHCII
2 isolated from a single dog with squamous cell carcinoma (3A), prostatic adenocarcinoma (3B) and osteosarcoma (3C). Non-
stimulated PBMCs were used as negative control and PBMCs stimulated in absence of CD11b
+CD14
2MHCII
2 cells were used as positive control for
proliferation. PBMCs were also co-incubated with PMNs, to control for presence of additional cells (3C, 3D). Proliferative responses were measured by
3H-thymidine incorporation. CPM, counts per minute. Amount of IFN-c secretion in the co-culture was determined using canine specific IFN-c ELISA
assay (3D). All experiments were performed in triplicate. Mean 6 SEM are shown.
doi:10.1371/journal.pone.0033274.g003
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+CD14
2MHCII
2 cells suppress T cell proliferation. Facs sorted CD11b
+CD14
2MHCII
2 cells isolated from a dog with
osteosarcoma or healthy PBMCs were co-incubated with mitogen-stimulated CD4
+ and CD8
+ T cells isolated from a healthy dog for 72 hs. No
stimulated cells were used as negative control. Proliferative responses were measured by
3H-thymidine incorporation from experiments performed in
triplicate. CPM, counts per minute. Mean 6 SEM are shown.
doi:10.1371/journal.pone.0033274.g004
Figure 5. CD11b
+CD14
2MHCII
2 cells express MDSC-derived immunosuppressive factors. RT-PCR analysis of FACS purified
CD11b
+CD14
2MHCII
2 cells detected expression of ARG1 and iNOS2, as well TGF-b and IL-10 immunosuppressive cytokines. ARG-1 expression
was not detected in normal PMNs. CD11b
+CD14
2MHCII
2 cells were isolated from the peripheral blood of a dog with osteosarcoma and PMNs were
isolated from a healthy dog. NRT, RNA template in the absence of reverse transcriptase. Results are representative three experiments.
doi:10.1371/journal.pone.0033274.g005
MDSCs in Dogs with Spontaneous Cancer
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suppression. This finding was not unexpected and has been
previously documented in human MDSC studies [19].
Discussion
The field of comparative oncology shows great promise to
advance the development of novel therapeutics for pet dogs and
human patients alike. However, the paucity of reagents and poorly
defined immunophenotype of canine leukocytes has restrained our
ability to understand tumor immunology in dogs with naturally
occurring cancer. Our data demonstrates the existence of MDSCs
in the peripheral blood of dogs, which are elevated in all types of
advanced or metastatic cancer analyzed compared to early stage
non-metastatic cancer and healthy controls. With this basic
foundation of knowledge in place, it will now be possible to
prospectively monitor MDSC burden in dogs treated with
experimental drugs and immunotherapy. The CD11b
+CD14
2
MHCII
2 cell population that we defined as MDSC co-purified
with PBMCs, had polymorphonuclear granulocytic morphology,
suppressed T cell proliferation and effector function, expressed
hallmark suppressive factors of human MDSC, and positively
correlated with tumor burden. Proliferation assays revealed
relatively weak proliferation in PBMCs from tumor-bearing dogs
(Fig. 3A,B) compared to normal responders (Fig. 3C) in the
absence of exogenous MDSC. This likely reflects elevated levels of
endogenous (not experimentally added) MDSCs and regulatory T
cells in the PBMCs from dogs with cancer. Furthermore, it is
crucial to note that a second subset of MDSC that is more
monocytic in nature is widely appreciated in murine and human
tumor immunology. We found no evidence for selective expansion
of a CD14
+ monocyte-like cell in the blood of dogs with cancer.
However, CD11b
+MHCII
2 cells that were purified from dogs
with advanced cancer that were also CD14
+ potently inhibited T
cell proliferation (Figure S2), revealing that although monocytic
MDSC are not a dominant population in dogs with cancer, they
are indeed present. This finding of preferential expansion of
granulocytic MDSC is not surprising and is in agreement with
similar studies carried out in murine tumor models [15]. Overall,
our data are consistent with a global state of immune suppression
in dogs with advanced cancer that is likely attributable to several
mechanisms.
The practical deliverable of this study is a simple three marker
surface immunophenotype that can be used to prospectively
monitor MDSC burden in dogs. We have performed pilot studies
to look for additional markers. Specific preliminary results that are
worth noting are as follows. We have been unable to demonstrate
successful staining using anti-human CD66b antibodies. CD66b is
an activation marker expressed on some human MDSC [19]. The
most widely used marker for MDSC in the mouse is Gr-1, and an
antibody against mouse Gr-1 cross-reacts nicely with canine cells,
as does anti-mouse CD11b (Figure S1). Further studies will be
required to determine if canine cells that are identified by anti-
mouse Gr-1 and CD11b antibodies are indeed MDSCs.
One potential limitation of this study that many of the samples
we analyzed were frozen, the thawed before analysis, which could
have influenced cell viability. However, freeze-thaw did not
significantly affect cell viability of either granulocytic or monocytic
MDSC (Figure S3). We consider this a positive finding because
canine MDSCs could be frozen from multiple time points in future
prospective studies, then thawed and analyzed simultaneously to
limit batch to batch variability. A second limitation is that the RT-
PCR analysis of immunosuppressive molecules was qualitative,
was performed on a small number of dogs (Table S3), and was
not a direct comparison to matched healthy cells. We were not
able to obtain adequate viable CD11b
+CD14
2MHCII
2 cells from
healthy dogs by FACS to directly compare to the same population
from dogs with cancer due to their low frequency and apparently
high rate of cell death following FACS. For this reason, normal
PMNs isolated by gradient centrifugation were used for compar-
ison in our studies. Quantitative mechanistic studies should be
conducted to dissect which of the candidate molecules studied
herein mediate T cell suppression. Additionally, some of the dogs
had received treatment for their cancer. This is relevant because
MDSC levels in human cancer patients have been shown to be
influenced by prior therapy. It is also known that tumor burden
and inflammation significantly affect circulating MDSC levels.
Studies in mice have shown that accumulation and suppressive
activity of MDSCs are regulated by the inflammatory milieu [20].
Thus treatment, such as surgical excision of the tumor,
chemotherapy, and nonsteroidal anti-inflammatory drug (NSAID)
administration, can alter the levels of these cells in the peripheral
blood. Evaluation of the medical records of dogs in our study
revealed that many dogs received some therapy prior to blood
sample collection, which could have affected the levels of MDSCs
in these samples (see Tables S1 and 2S). However, Figure S4
demonstrates that treatment of dogs with advanced cancer did not
significantly alter MDSC burden relative to dogs that had not been
previously treated. Therefore, our study provides evidence that
expanded MDSCs are likely a robust, general feature of cancer in
canines despite genetic heterogeneity and a range of previous
treatments (or lack of previous treatment).
In summary, we have identified a granulocytic subset of cells
with immunosuppressive function that are elevated in dogs with
advanced cancer that can be characterized as MDSCs. Canine
MDSCs may be a potential target for therapeutic interventions in
dogs with cancer. Furthermore, the study of MDSCs in dogs
treated with experimental therapies should reveal unique insights
into what might be expected in human patients. This cross-species
comparison provides an attractive opportunity to move the field of
translational medicine forward.
Supporting Information
Figure S1 Mouse anti-CD11b and Gr-1 antibodies cross-
react with canine samples. Fresh PBMCs from healthy dog
and cancer patients were isolated by Ficoll, stained with anti-
mouse CD11b and anti-mouse Gr-1 antibodies.
(TIF)
Figure S2 CD11b
+CD14
+MHCII
2 cells demonstrate
ability to suppressive T cell proliferation. (A)
CD11b
+CD14
+MHCII
2 cells were sorted from peripheral blood
sample of an osteosarcoma dog (B) and co-cultured with healthy
dog PBMCs in the presence of mitogen for 72 hs. Non-stimulated
PBMCs were used as negative control and PBMCs co-cultured
with healthy PMNs were used to control for the effect of adding
cells to the assay. Proliferative responses were measured by
3H-
thymidine incorporation. CPM, counts per minute. The experi-
ment was performed in triplicate. Mean 6 SEM are shown.
(TIF)
Figure S3 Frequency of MDSCs measured was not
significantly altered by cryopreservation. MDSC percent-
ages in fresh and frozen samples were assessed for comparison.
Mean 6SEM are shown.
(TIF)
Figure S4 No significant effect of pretreatment on
MDSC burden. Analysis of the average CD11b
+CD14
2
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2 population frequency in treated (n=17) or untreated
dogs with advanced stage or metastatic tumors (n=13) compared
to control dogs (n=18). There was a significantly higher
percentage of CD11b
+CD14
2MHCII
2 cells in dogs with
advanced cancer treated or untreated compared to healthy dogs
(32.6963.24%, 40.4263.86% vs. 10.2461.412%, respectively).
N.S., not statistically significant (there was no significant difference
between samples that had been treated compared to those from
untreated samples). Mean 6 SEM are shown (* indicates
P,0.0001).
(TIF)
Table S1 Summary data for dogs with advanced stage
or metastatic tumors.
(DOC)
Table S2 Summary data for dogs with early stage non-
metastatic tumors.
(DOC)
Table S3 Table of cancer patient samples and the
experiment in which the PBMCs were used.
(DOC)
Table S4 Primer sequences for genes evaluated by
semi-quantitative PCR.
(DOC)
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